The Second Affiliated Hospital of University of South China, Hengyang, 421001, Hunan, China.
Sci Rep. 2023 Sep 26;13(1):16073. doi: 10.1038/s41598-023-43427-w.
Coagulation system activation is commonly observed in tumor patients, including prostate cancer (PCa), with coagulation markers proposed as potential prognostic indicators for cancer severity. However, the correlation between these markers and clinicopathological features in PCa remains unclear. Thus, this study investigates the association between comprehensive coagulation markers and clinicopathological characteristics in PCa patients. A retrospective evaluation of 162 PCa patients diagnosed and categorized into low-intermediate-risk or high-risk groups based on clinical and pathological features was conducted. Coagulation markers, including fibrinogen (FIB), D-dimer (DD), activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin activity (PTA), thrombin time (TT), platelet count (PLT), and international normalized ratio (INR), were assessed. Univariate and multivariate logistic regression analyses were performed to determine associations with clinicopathological features. FIB and DD were confirmed as independent factors associated with high-risk PCa. Furthermore, FIB and DD levels showed significant positive correlations with clinical parameters, including PSA levels, ISUP grade, T stage, N stage, and M stage. Our findings suggest that FIB and DD hold promise as independent prognostic biomarkers for risk stratification in PCa. These coagulation markers may aid in assessing PCa severity and guiding personalized treatment strategies.
凝血系统激活在肿瘤患者中很常见,包括前列腺癌(PCa),凝血标志物被提出作为癌症严重程度的潜在预后指标。然而,这些标志物与 PCa 的临床病理特征之间的相关性尚不清楚。因此,本研究探讨了综合凝血标志物与 PCa 患者临床病理特征之间的关系。对 162 例 PCa 患者进行了回顾性评估,根据临床和病理特征将其分为低-中危组或高危组。评估了凝血标志物,包括纤维蛋白原(FIB)、D-二聚体(DD)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶原活性(PTA)、凝血酶时间(TT)、血小板计数(PLT)和国际标准化比值(INR)。进行了单因素和多因素逻辑回归分析,以确定与临床病理特征的关联。FIB 和 DD 被确认为与高危 PCa 相关的独立因素。此外,FIB 和 DD 水平与临床参数(包括 PSA 水平、ISUP 分级、T 分期、N 分期和 M 分期)呈显著正相关。我们的研究结果表明,FIB 和 DD 有望成为 PCa 风险分层的独立预后生物标志物。这些凝血标志物可能有助于评估 PCa 的严重程度并指导个体化治疗策略。